Introduction. Epilepsy is one of the most common neurological diseases in the world and requires appropriate medical treatment. The Global Burden of Epilepsy Report estimates that there are 13 million disability adjusted life years due to epilepsy each year. Epilepsy is an important medical, social and economic problem of modern society, the solution of which is often based on the use of antiepileptic drugs. According to the State Strategy for the implementation of the state policy of providing the population with medicines for the period until 2025, the cost of medicines is an important factor that ensures their financial availability for the population. This determined the relevance of this stage of the research.Material & methods. Materials: information about purchase prices (Pp) for antiepileptic drugs of wholesale pharmaceutical enterprises (WPE 1, WPE 2 and WPE 3), which at the time of the study were in the TOP-3 in terms of the volume of drug supplies to pharmacies.  Methods: information search, comparison, analysis, generalization, determination of the cost of defined daily dose (DDD). The study period was February 2023. Results & discussion. It was found that at the time of the research, the TOP-3 WPE offered 105 assortment items (AI) of 11 international non-proprietary names of antiepileptic drugs in their price lists, taking into account the dosage forms and doses. By studying the DDD Pp of antiepileptic drugs AI, it was established that the largest number of AI with the lowest DDD Pp was offered by WPE 1 – 34 AI (or 32.38% of the total number of analyzed drugs). At the same time, in 26 AI (24.76%) offered by WPE 2, the cost of DDD was lower than that of competitors. The most valuable were the offers of WPE 3. It was found that among the 36 AI of pregabalin, the lowest DDD Pp was inherent in 15 and 8 AI, offered by WPE 1 and WPE 2, respectively. The price range of AI pregabalin DDD ranged from UAH 18.60 ("Pregabalin-Darnytsia", capsules 300 mg No. 21, PJSC Pharmaceutical company Darnytsia (Ukraine), the lowest price offer of WPE 1) to UAH 58.28 ("Galara", capsules 75 mg No. 14, WORLD MEDICINE İLAÇ SAN. VE TİC. A.Ş. (Turkey), the highest price offer of WPE 3).  The calculated values of Cliq ranging from 0.002 to 0.17 and Iаv from 5.68% to 17.21% for AI of pregabalin indicate a high level of competition and relative economic availability of the analyzed antiepileptic drugs in the studied segment of the wholesale market. At the same time, using the matrix projection of the integrated Sliq / Iav analysis, 7 or 19.44% of pregabalin AI were determined, which were the most economically available in the TOP-3 offers of the WPE. Conclusion. A situational analysis of the economic availability of antiepileptic drugs was carried out on the example of assortment offers of the TOP-3 wholesale pharmaceutical enterprises of Ukraine.

Introduction. Epilepsy, as a chronic non-infectious disease of the brain, affects according to some data about 50 million, according to others - about 65 million people worldwide. Epilepsy can be treated with antiepileptic drugs (AEDs), diet therapy, and surgery. AEDs are drugs of various origin, which are used to prevent or reduce (in intensity and frequency) seizures, their corresponding equivalents (loss or disturbance of consciousness, behavioral and autonomic disorders, etc.), which are observed during periodically occurring attacks of various forms of epilepsy. The peculiarity of the treatment of epilepsy is the need for regular daily intake of AEDs for many years, including at least 3-5 years after the cessation of seizures. The number of patients forced to take AEDs during whole life reaches 15%. Material & methods. The sources of information were: domestic and foreign web resources, the State Register of Medicines of Ukraine (for searching of AEDs) (as of February 1, 2023), registers of drugs which are subjects to reimbursement under the medical guarantee program. The several methods were used in the research, such as: information search, comparison, analysis, generalization, marketing.  Results & discussion. The analytical study of AEDs showed that in Ukraine as of February 1, 2023, were registered 325 trade names (TN) of AEDs, which represented 16 international non-propriatory names (INN). About half (48.85%) of the researched assortment is made by pregabalin-based medicines. Almost one-eighth parts of the assortment (12.92% each) is taken by lamotrigine and levitiracetam TN. In total, drugs of these three INNs make up about 72% of the nomenclature of AEDs. The distribution of the studied assortment by dosage forms type showed that the absolute majority of AEDs was represented by capsules (51.08%) and tablets (45.23%).  It was established that three-quarters (75.38%) of the nomenclature of AEDs are drugs of foreign production. They are represented by 65 companies from 23 countries of the world. Among them, the vast majority (88.57%) are produced by one company, a tenth part (10.20 %) – by two-three manufacturers, and three TN of Pregabalin euro (1.22 %) – by 13 enterprises. As for domestic medicines, they are represented by 13 manufacturers, and 9 out of 10 (93.75%) of their products are made by one, and the rest by two companies. High production activity regarding AEDs is characteristic of enterprises from India (16.67% of manufacturers, Index of Production Activity (IPA) = 26.28%) and Ukraine (16.67% of manufacturers, IPA = 22.96%). Among foreign enterprises, the highest production activity has Dr. Reddy's Laboratories Limited, India (IPA = 6.63%), and among Ukrainian manufacturers - LLC "Pharma Start" (IPA = 3.83%). As a result of the data analysis of 5 Registers of medicines, the prices of which are subject to reimbursement under the program of state guarantee program of medical care of the population for 2021-2023, an increase in the number of AEDs INN from 3 to 4 was found. The analysis of the latest Register as of August 10, 2023 showed that it included 31 TN of these drugs (lamotrigine – 18, carbamazepine – 10, valproic acid – 2 and phenytoin – 1). At the same time, patients with epilepsy can receive 10 medicines free of charge, with a surcharge of up to 10% of the cost - 1 medicine, with a surcharge of 10-20% - 4 medicines, 21-30% - 10 medicines, 31-40% - 2 medicines and in within 41-50% - 4 medicines. Conclusion.  Separate components of the marketing complex regarding antiepileptic drugs registered in Ukraine and their role in the context of the program of state guarantee program of medical care of the population were studied.